Abstract 2559
Background
The APACT trial compared disease-free survival in pts with surgically resected PA randomized to nab-P+GEM or GEM as adjuvant regimens. We compared the QoL impact of both regimens in the biggest cohort of pts (n = 379/arm) in which QoL was studied in this setting.
Methods
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and pancreatic cancer module (PAN26) scores were assessed in 12-week intervals at screening (BL), middle and end of treatment (EOT), and up to 2.5 years of follow-up (FU). A mixed model for repeated measures analysis adjusting for BL score was conducted to predict scores by arm at each visit. Time until definite deterioration (TUDD) and improvement (TUDI) were compared between arms, separately during treatment and FU, using a minimal important difference (MID) threshold of 10-points for all QLQ-C30 scales and scale-specific thresholds for PAN26.
Results
The proportion of pts with QoL data at EOT, year 1, and year 3 were 88%, 51%, and 17%, with similar attrition in both arms. The predicted differences between arms for global health (GH) and all but 1 subscale of the QLQ C-30 never reached the predefined MID threshold (Table). nab-P+GEM pts had meaningfully worse predicted scores than GEM pts on 6 of 17 PAN26 scales during treatment, but these differences persisted for only 2 scales at 2 FU visits. For TUDD and TUDI, nab-P+GEM pts deteriorated faster during treatment, but TUDD did not differ for domain-specific or GH scales between arms at FU, during which nab-P+GEM pts improved faster on some scales, including GH.Table:
684P QLQ-C30 and PAN26 scales assessed through MMRM, TUDD, and TUDI analyses demonstrating clinically and statistically significant differences between nab-P+GEM vs GEM
nab-P+GEM vs GEM Comparison | During Treatmenta | Follow-Upb | |||
---|---|---|---|---|---|
QLQ-C30 | PAN26 | QLQ-C30 | PAN26 | ||
MMRM analysis by arm: scales with clinically and statistically significant differences in mean predicted scoresc | Favoring GEM | RFe (67 vs 78 at MOT) | BIf (33 vs 22 at MOT) TAf (28 vs 15 at EOT) WEf (33 vs 23 at EOT) LAf (28 vs 18 at EOT) AEf (34 vs 25 at EOT) SXf (38 vs 31 at EOT) | - | TAf (19 vs 11 at w48) LAf (25 vs 16 at w36) |
Favoring nab-P+GEM | - | - | - | - | |
TUDD: scales with significant differences (hazard ratios for nab-P+GEM vs GEM)d,g | Favoring GEM | GH (1.4) PF (1.8) RF (1.4) SF (1.5) DY (1.5) | BI (1.7) TA (2.0) WE (2.3) AE (1.6) LA (1.3) SX (1.4) | - | - |
Favoring nab-P+GEM | - | PP (0.7) | - | LW (0.8) WE (0.6) | |
TUDI: scales with significant differences (hazard ratios for nab-P+GEM vs GEM)d,h | Favoring GEM | GH (0.5) PF (0.5) RF (0.6) SF (0.6) FA (0.6) PA (0.7) AL (0.7) | DS (0.8) BI (0.5) SX (0.5) TA (0.5) WE (0.4) DM (0.7) AE (0.6) FH (0.6) LA (0.6) | - | - |
Favoring nab-P+GEM | - | - | GH (1.7) PF (1.6) RF (1.4) SF (1.4) FA (1.4) | BI (1.6) SX (1.4) TA (1.7) IN (1.6) WE (2.1) LA (1.4) |
AE, treatment related adverse event; AL, appetite loss; BI, body image; DM, dryness of mouth; DS, digestive symptoms; DY, dyspnea; EOT, end of treatment; FA, fatigue; FH, worried about future health; GH, global health; IN, indigestion; LA, limited activities; MMRM, mixed model for repeated measures; MOT, middle of treatment; PA, pain; PF, physical function; PP, Pancreatic Pain; RF, role function; SF, social function; SX, sexual dysfunction; TA, taste change; TUDD, time until definite deterioration; TUDI, time until definite improvement; WE, weakness in arms and legs. w36 or w48 = clinically and statistically significantly up to week 36 or week 48. a During treatment = MOT and EOT. b Follow-up = EOT to week 156. c Mean predicted scores for nab-P+GEM vs GEM for visits until clinical and statistical differences persisted. d Hazard ratio not including 1.00. e Higher score indicates better QoL. f Higher score indicates worse QoL. g Hazard Ratio >1 indicate higher rate of deterioration and <1 indicate lower rate of deterioration in nab-P+GEM h Hazard Ratio >1 indicate higher rate of improvement and <1 indicate lower rate of improvement in nab-P+GEM
Conclusions
As expected, nab-P+GEM is associated with temporary reductions in some QoL dimensions vs GEM alone. Over the long term, QoL was not compromised by adding nab-P to GEM as adjuvant therapy for surviving and reporting pts.
Clinical trial identification
ABI-007-PANC-003.
Editorial acknowledgement
Pharmerit International.
Legal entity responsible for the study
The authors.
Funding
Celgene Corporation.
Disclosure
H. Riess: Advisory / Consultancy: Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Daiichi-Sankyo, Johnson & Johnson, Pfizer; Speaker Bureau / Expert testimony: Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Celgene, Daiichi-Sankyo, Leo-Pharma, Pfizer; Research grant / Funding (institution): Bayer, Celgene, Leo Pharma. J. Braverman: Full / Part-time employment: Celgene Corporation. M. Reni: Non-remunerated activity/ies, Personal Fees: Celgene, Baxalta, Shire, eli-lilly, Pfizer, Novocure, Novartis, AstraZeneca. D. Oh: Advisory / Consultancy: Genentech/Roche, AstraZeneca, Novartis, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks; Research grant / Funding (institution): AstraZeneca, Novartis, Array, Eli Lilly. T. Macarulla Mercade: Honoraria (self): Roche, Sanofi, Tesaro, Shire, Genzyme; Advisory / Consultancy: Baxalta, Celgene, H3B, QED, Shire; Speaker Bureau / Expert testimony: Celgene, Sanofi/Aventis, Shire; Research grant / Funding (self): Agios, Aslan, AstraZeneca, Bayer, Celgene, Genetech, Hallozyme, Immunomedics, Lilly, Merimarck, Millennium, Novartis, Novocure, Pfizer, Pharmacyclics, Roche; Travel / Accommodation / Expenses: Bayer, H3B, Merck, Sanofi. A. Shah: Full / Part-time employment: Pharmerit International; Non-remunerated activity/ies, Financial Support: Bayer, Celgene, Pfizer, Insmed. N. Joshi: Full / Part-time employment: Pharmerit International; Advisory / Consultancy, Consulting Fee: Celgene Corporation. M. Botterman: Honoraria (institution): Celgene, Bayer, Daiichi, BMS. E. Mantovani: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. B. Lu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Celgene Corporation. M.A. Tempero: Advisory / Consultancy: AbbVie, Advance Medical, BioPharm Communications, BMS, Celgene, Eisai, Ignyta, Pharmacyslics, Pharmcyte Biotech, Tocagen; Advisory / Consultancy, Advisory Board: AstraZeneca, CPRIT, Immunovia; Research grant / Funding (self), Research Contract: Halozyme. All other authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract